Special Issue

Advances and Challenges in RAS-Directed Cancer Therapy

Message from the Guest Editors

Oncogenic RAS mutations, such as G12C, G12D, G13D, and Q61H, are some of the most frequently mutated genes causing cancer. Multiple strategies have been developed to directly target the aberrant activation of RAS signaling to treat cancer, including prenylation inhibitors, PDE□ inhibitors, and SHP2 inhibitors, but none have advanced to use in the clinic. Recently approved KRAS G12C inhibitors justified KRAS as a target and, significantly, demonstrated that specific RAS mutant can be selectively targeted. However, KRAS G12C is the only RAS mutant that has been successfully targeted so far in human cancer patients, which limits its application for targeting other oncogenic RAS mutant-driven cancers. This Special Issue will cover subjects related to recent progress in RAS-directed therapeutic approaches in cancer therapy and the underlying mechanisms for acquired drug resistance. The hope is that it will increase our understanding of the clinical efficacy and challenges of RAS targeting therapy in different cancers.

Guest Editors

Dr. Zhiwei Zhou

Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA

Dr. Xi Wei

1. Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China
2. Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

Deadline for manuscript submissions

closed (10 August 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/181453

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)